Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

International trade fair launch with CARL in London

On the occasion of the 10th EuroELSO Congress from May,4th to May, 6th in London, Resuscitec GmbH successfully presented CARL for the first time at an international trade fair. At the large lunch symposium, participants were able to learn about the first in-hospital and out-of-hospital uses of the CARL system during presentations by Alois Philipp from the University Hospital Regensburg and Hug Aubin from the University Hospital Düsseldorf.

At the large lunch symposium, participants were able to learn about the first in-hospital and out-of-hospital uses of the CARL system during presentations by Alois Philipp from the University Hospital Regensburg and Hug Aubin from the University Hospital Düsseldorf. Alois Philipp reported about 14 patients who were treated with CARL system outside the hospital. One patient was treated in an external hospital. Nine of these patients could be discharged after an average hospital stay of 24 days.

The training units offered aroused great interest: In several courses per day, the participants were able to get to know CARL in a real-clinical setting and then discuss specific questions with our support and sales team on site.

< Back

Close